- Home
- SGN vs SCNI Comparison
SGN vs SCNI Comparison
Compare SGN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SCNI
- Stock Information
- Founded
- SGN 2019
- SCNI 2003
- Country
- SGN United States
- SCNI Israel
- Employees
- SGN N/A
- SCNI N/A
- Industry
- SGN
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGN
- SCNI Health Care
- Exchange
- SGN Nasdaq
- SCNI Nasdaq
- Market Cap
- SGN 4.1M
- SCNI 3.5M
- IPO Year
- SGN 2023
- SCNI N/A
- Fundamental
- Price
- SGN $3.11
- SCNI $3.39
- Analyst Decision
- SGN
- SCNI
- Analyst Count
- SGN 0
- SCNI 0
- Target Price
- SGN N/A
- SCNI N/A
- AVG Volume (30 Days)
- SGN 79.0K
- SCNI 13.0K
- Earning Date
- SGN 12-24-2024
- SCNI 11-22-2024
- Dividend Yield
- SGN N/A
- SCNI N/A
- EPS Growth
- SGN N/A
- SCNI N/A
- EPS
- SGN N/A
- SCNI 8.20
- Revenue
- SGN $576,488.00
- SCNI $452,000.00
- Revenue This Year
- SGN N/A
- SCNI N/A
- Revenue Next Year
- SGN N/A
- SCNI N/A
- P/E Ratio
- SGN N/A
- SCNI $0.42
- Revenue Growth
- SGN 147.76
- SCNI N/A
- 52 Week Low
- SGN $2.80
- SCNI $2.23
- 52 Week High
- SGN $73.44
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SGN 31.18
- SCNI 51.16
- Support Level
- SGN $2.80
- SCNI $3.20
- Resistance Level
- SGN $3.59
- SCNI $3.55
- Average True Range (ATR)
- SGN 0.84
- SCNI 0.19
- MACD
- SGN -0.08
- SCNI 0.02
- Stochastic Oscillator
- SGN 5.34
- SCNI 47.50
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.